In a recent randomized controlled study in primary care (BEST3 trial), Cytosponge-TFF3 led to a 10-fold increase in the diagnosis of Barrett’s esophagus (BE) among patients with reflux symptoms.5 This evidence concerns the gene TFF3 and Barrett esophagus.